SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-093554
Filing Date
2023-08-18
Accepted
2023-08-18 17:16:15
Documents
15
Period of Report
2023-08-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2324079d1_8k.htm   iXBRL 8-K 24144
2 EXHIBIT 3.1 tm2324079d1_ex3-1.htm EX-3.1 7592
6 GRAPHIC tm2324079d1_ex3-1img001.jpg GRAPHIC 100437
7 GRAPHIC tm2324079d1_ex3-1img002.jpg GRAPHIC 14264
  Complete submission text file 0001104659-23-093554.txt   358135

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scps-20230814.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20230814_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20230814_pre.xml EX-101.PRE 22373
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2324079d1_8k_htm.xml XML 3228
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39788 | Film No.: 231186704
SIC: 2834 Pharmaceutical Preparations